Literature DB >> 11999358

Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome.

Krishnan Allampallam1, Vilasini Shetty, Suneel Mundle, Diya Dutt, Howard Kravitz, Poluru L Reddy, Sairah Alvi, Naomi Galili, Gurveen S Saberwal, Shalini Anthwal, Maliha W Shaikh, Aaron York, Azra Raza.   

Abstract

Labeling index (LI), apoptosis, levels of 2 pro-apoptotic cytokines tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta(TGF-beta), and the number of monocyte/macrophage cells that are the likely source of the cytokines were simultaneously measured in plastic-embedded bone marrow (BM) biopsy sections of 145 patients with myelodysplastic syndromes (MDS). TNF-alpha was correlated with TGF-beta (P = .001) and with monocyte/macrophage cells (P = .003). Patients with excess blasts in their marrows had a higher TGF-beta level (P = .01) and monocyte/macrophage number (P = .05). In a linear regression model,TGF-beta emerged as the most significant biological difference between patients who have excess of blasts and those who do not (P = .01). We conclude that in addition to TNF-alpha, TGF-beta also plays a significant role in the initiation and pathogenesis of MDS, and that a more precise definition of its role will likely identify better preventive and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999358     DOI: 10.1007/bf02982044

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  32 in total

Review 1.  Myelodysplastic syndromes.

Authors:  J F San Miguel; G F Sanz; T Vallespí; M C del Cañizo; M A Sanz
Journal:  Crit Rev Oncol Hematol       Date:  1996-05       Impact factor: 6.312

2.  Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia.

Authors:  A Raza; N Yousuf; S Bokhari; A Abbas; B Lampkin; J Pancoast; J Bismayer; C Siegrist; G Browman; J Bennett; J Goldberg; H Grunwald; R Larson; G Tricot; R Vogler; P Gartside; H Preisler
Journal:  Int J Oncol       Date:  1993-02       Impact factor: 5.650

3.  Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.

Authors:  S D Mundle; B Y Mativi; K Bagai; G Feldman; P Cheema; U Gautam; S Reza; J D Cartlidge; P Venugopal; V Shetty; S A Gregory; E Robin; S Rifkin; R Shah; A Raza
Journal:  Int J Hematol       Date:  1999-08       Impact factor: 2.490

4.  Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.

Authors:  M Herold; F Schmalzl; H Zwierzina
Journal:  Leuk Res       Date:  1992 Jun-Jul       Impact factor: 3.156

5.  Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration.

Authors:  C M Peddie; C R Wolf; L I McLellan; A R Collins; D T Bowen
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

Review 6.  Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.

Authors:  A Raza
Journal:  Microsc Res Tech       Date:  2000-08-01       Impact factor: 2.769

7.  Low frequency of myeloid progenitor cells in chronic idiopathic neutropenia of adults may be related to increased production of TGF-beta1 by bone marrow stromal cells.

Authors:  H A Papadaki; K Giouremou; G D Eliopoulos
Journal:  Eur J Haematol       Date:  1999-09       Impact factor: 2.997

8.  Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes.

Authors:  K Allampallam; V Shetty; S Hussaini; L Mazzoran; F Zorat; R Huang; A Raza
Journal:  Anticancer Res       Date:  1999 Nov-Dec       Impact factor: 2.480

9.  A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.

Authors:  G M Gersuk; C Beckham; M R Loken; P Kiener; J E Anderson; A Farrand; A B Troutt; J A Ledbetter; H J Deeg
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

10.  Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes.

Authors:  S D Mundle; P Venugopal; J D Cartlidge; D V Pandav; L Broady-Robinson; S Gezer; E L Robin; S R Rifkin; M Klein; D E Alston; B M Hernandez; D Rosi; S Alvi; V T Shetty; S A Gregory; A Raza
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

View more
  32 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Authors:  Li Zhou; Christine McMahon; Tushar Bhagat; Cristina Alencar; Yiting Yu; Melissa Fazzari; Davendra Sohal; Christoph Heuck; Krishna Gundabolu; Chun Ng; Yongkai Mo; Wa Shen; Amittha Wickrema; Guanghui Kong; Ellen Friedman; Lubomir Sokol; Ioannis Mantzaris; Giannis Mantzaris; Andrea Pellagatti; Jacqueline Boultwood; Leonidas C Platanias; Ulrich Steidl; Lei Yan; Jonathan M Yingling; Michael M Lahn; Alan List; Markus Bitzer; Amit Verma
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

3.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 4.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 5.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

6.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Hanna J Khoury; Elias Jabbour; Jeffrey Lancet; Shannon L Winski; LouAnn Cable; Selena Rush; Lara Maloney; Grant Hogeland; Mieke Ptaszynski; Monica Cabrero Calvo; Zach Bohannan; Alan List; Hagop Kantarjian; Rami Komrokji
Journal:  Clin Cancer Res       Date:  2014-12-05       Impact factor: 12.531

8.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Authors:  Minyoung Youn; Haigen Huang; Cheng Chen; Sharon Kam; Mark C Wilkes; Hee-Don Chae; Kunju J Sridhar; Peter L Greenberg; Bertil Glader; Anupama Narla; Shuo Lin; Kathleen M Sakamoto
Journal:  Blood Adv       Date:  2019-09-24

9.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Authors:  A Mario Marcondes; Andrew J Mhyre; Derek L Stirewalt; Soo-Hyun Kim; Charles A Dinarello; H Joachim Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.

Authors:  Janice Gabrilove; Ronald Paquette; Roger M Lyons; Chaudhry Mushtaq; Mikkael A Sekeres; Dianne Tomita; Lyndah Dreiling
Journal:  Br J Haematol       Date:  2008-06-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.